A 74-year-old womanwas admitted with an asthma attack. She had a 40-year history of sinusitis, nasal polyp and analgesic-induced asthma; however, asthma had never occurred when she used a 0.3% ketoprofen adhesive patch (Mohrus®) for stiff shoulder or lumbago. In the hospital, a life-threatening asthma attack suddenly occurred two and a half hours after application of a 2.0% ketoprofen adhesive tape (Mohrus tape®) to her shoulder. She was treated with bronchodilator and glucocorticoid and extubated after 20 hours. A drug lymphocyte stimulating test (DLST) was strongly positive for ketoprofen. Wesuspected that drug-induced hypersensitivity coexisted in the present case, but it was not clear whether or not the hypersensitivity was related to the pathogenesis of analgesic-induced asthma. (Internal Medicine 40: 124-126, 2001) 
Introduction
The drugs most commonlyassociated with acute induction of asthma are nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin, coloring agents such as tartrazine, beta-adrenergic antagonists and sulfiting agents ( 1) . Approximately 1-10% of patients with bronchial asthma are potentially susceptible to analgesic-induced asthma, also knownas "aspirininduced asthma" (2) (3) (4) . Recently, there have been a few reports in which transdermal absorption type NSAIDs (ketoprofen) adhesive patches or skin lotion, have led to aspirin-induced asthma (5, 6) . While the mechanism by which NSAIDselicit bronchospasms is not clear, immediate hypersensitivity does not seem to be involved (1 Inc., Saga) to her shoulder at 3:00 PMon October 5, 1999, but stripped it off at 4:00 PMbecause she felt a burning pain on the shoulder. There were no skin reactions associated with immediate-type hypersensitivity. At 5:30 PM, she had a sudden onset of severe dyspnea and became unconscious requiring mechanical ventilation, with urinary and fecal incontinence. Analysis of arterial blood showed severe hypoxemia and hypercapnia (pH 7.03, PaO2 50.1 Torr, PaCO2 118.9 Torr, HCO3 28.9 mmol//). Chest roentgenogram on intubation showed no abnormality ( Fig. 1) . She was extubated after 20 hours to im-Asthma Due to Ketoprofen Adhesive Tape prove arterial blood gas by treatment with 500 mg of aminophylline and 400 mg of hydrocortisone sodium succinate intravenously. Challenge and patch tests were not performed because adhesive agents had led to a life-threatening asthma attack. A drug lymphocyte stimulating test (DLST) was strongly positive for ketoprofen. In addition, the results were also positive for oxybenzoneand rosin glycerin ester, which are addi tives in ketoprofen adhesive agents (Table 1) .
Discussion
Analgesic-induced asthma is a life-threatening condition. I has been reported that this disease accounts for 20% of near death attacks in asthma (4) and 8% of asthma attacks requiring mechanical ventilation (7) . Indomethacin, fenoprofen naproxen, ibuprofen and mefenamicacid are related to anal gesic-induced asthma. Ketoprofen, which is a 2-(3-benzoyl phenyl) propionic acid, had also been reported to be related t( this condition 20 years ago (8) . The renal contribution to th( plasma clearance of free ketoprofen is thought to be about 109? and ketoprofen is excreted via urine as a form of ketoprofer glucuronide (9) . In addition to oral, intramuscular and recta administration, transdermal absorption type ketoprofen adhe sive patches or skin lotion have becomeknownto be ralated tc analgesic-induced asthma. As noted in the article by Tanaka e al (5), Miyairi et al were the first to report, in 1990, a case oi analgesic-induced asthma due to transdermal absorption-type ketoprofen ointment. To the best of our knowledge, there have been two reports in which ketoprofen adhesive patches or skir lotions, have led to analgesic-induced asthma. In one report < 40-year-old womanhad a life-threatening asthma attack 5 hour? after use of a ketoprofen adhesive patch (5) and in the other i 40-year-old womanhad an attack of asthma 3 hours after application of ketoprofen lotion on skin (6) . In the present case although she felt a burning pain on the shoulder and striped of] the ketoprofen adhesive agents one hour later, she had a severe asthma attack requiring mechanical ventilation after a furthei 90 minutes. The 3-5 hour interval is characteristic of analgesic-induced asthma after the use of transdermal absorption-type NSAIDs agents.
It is especially noteworthy that a life-threatening asthma attack in this case was induced by 2.0%ketoprofen adhesive agents, but not by 0.3% agents. The maximal concentratior (Cmax) and time to maximal concentration (Tmax) of ketoprofer in serum when0.3% ketoprofen adhesive patches were usec on the back were 43.1 ng/ml and 12 hours. Cmaxand Tmax o1 2.0% ketoprofen adhesive agents were 135.9 ng/ml and 12." hours (unpublished data). Tanaka et al (5) reported that serurr ketoprofen levels on the occasion of severe attacks (81.7 ng/ ml) were higher than after use of 0.3% ketoprofen adhesive agents (Miltax®, Daiichi Pharmaceutical Co., Ltd., Saitama) in healthy volunteers. Wecould not collect blood samples to measure the levels during severe attack. However it is possible to speculate that the difference between serum ketoprofen levels when using 0.3% and 2.0% adhesive agents is related to whether or not analgesic-induced asthma occurs. In addition, there were no skin reactions associated with immediate-type hypersensitivity. Those facts confirmed that analgesic-induced asthma is a dose-dependent disease and is not only related to immediatetype hypersensitivity. Onthe other hand, it has been reported that the effect of NSAIDs, including ketoprofen, is related to the capacity to inhibit both the constitutive and inducible isoforms of cyclo-oxygenase (prostaglandin H synthase~l and 2) and that the inhibition triggers specific bronchoconstriction whichleads to a severe asthma attack (10). Szczeklik (ll) reported that the capacity to inhibit cyclo-oxygenase is related to the extent of asthma attack. However in the present case, a DLSTwas strongly positive for ketoprofen. In addition, dibutylhydroxytoluene and rosin ester are additives which are only contained in 2.0% ketoprofen adhesive tapes and a DLSTof rosin ester was weakly positive. L-menthol and oxybenzone are additives contained in both 0.3% and 2.0% adhesive agents, a DLSTof oxybenzone was also positive. It has been reported that many drug additives such as tartrazine, paraben, sodium benzoate and sulfite (NaHSO3), are related to analgesic-induced asthma, although they do not have the capacity to inhibit cyclooxygenase (1). The fact that only high-dose ketoprofen adhesive agents caused life-threatening asthma makes it possible to hypothesize that only products which only contain high-dose adhesive agents, dibutylhydroxytoluene or rosin ester, cause severe attacks. A DLSTof the latter was weakly positive, but it has not beenreported that rosin ester wasrelated to analgesicinduced asthma. Wesuspected that drug-induced hypersensitivity coexisted with analgesic-induced asthma in the present case, but it is not clear whether or not the hypersensitivity was related to the pathogenesis of the asthma. Elimination from the environment of the causative agents of analgesic-induced asthma would be the most successful means to treat this disease. Bronchodilators and glucocorticoids are also available for treatment of analgesic-induced asthma as well as for of conventional asthma. However, glucocorticoids should be used with caution in patients with analgesic-induced asthma; in some cases cross-sensitivity to steroid succinate esters has been reported (12) . The present patient was extubated after 20 hours by administration of 500 mgof aminophylline and 400 mgof hydrocortisone sodium succinate because she had no cross-sensitivity of steroid succinate esters. The fact that the interval from intubation to extubation is shorter in analgesic-induced asthma than in conventional asthma may be one of the characteristics of this disease.
While it is commonlyknown that NSAIDsare contraindicated in patients with analgesic-induced asthma, it is not well knownwhether or not NSAIDsadhesive patches can cause lifethreatening asthma. Even if patients with analgesic-induced asthma have been using some NSAIDsadhesive patch, other adhesive agents containing the sameNSAIDs are not necessarily safe at higher doses. Wesuggest that NSAIDsadhesive patches were presented with caution in bronchial asthma patients and only after confirming the absence of a history of analgesic-induced asthma.
